90 related articles for article (PubMed ID: 26210521)
1. Breast cancer after prophylactic mastectomy (bilateral or contralateral prophylactic mastectomy), a clinical entity: presentation, management, and outcomes.
Mutter RW; Frost MH; Hoskin TL; Johnson JL; Hartmann LC; Boughey JC
Breast Cancer Res Treat; 2015 Aug; 153(1):183-90. PubMed ID: 26210521
[TBL] [Abstract][Full Text] [Related]
2. A model for individualized risk prediction of contralateral breast cancer.
Chowdhury M; Euhus D; Onega T; Biswas S; Choudhary PK
Breast Cancer Res Treat; 2017 Jan; 161(1):153-160. PubMed ID: 27815748
[TBL] [Abstract][Full Text] [Related]
3. Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG)
Lancet; 2015 Oct; 386(10001):1341-1352. PubMed ID: 26211827
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG)
Lancet; 2015 Oct; 386(10001):1353-1361. PubMed ID: 26211824
[TBL] [Abstract][Full Text] [Related]
5. Contralateral Prophylactic Mastectomy: Challenging Considerations for the Surgeon.
Angelos P; Bedrosian I; Euhus DM; Herrmann VM; Katz SJ; Pusic A
Ann Surg Oncol; 2015 Oct; 22(10):3208-12. PubMed ID: 26259752
[TBL] [Abstract][Full Text] [Related]
6. Outcomes with and without axillary node dissection for node-positive lumpectomy and mastectomy patients.
Snow R; Reyna C; Johns C; Lee MC; Sun W; Fulp WJ; Kiluk JV; Laronga C
Am J Surg; 2015 Oct; 210(4):685-93. PubMed ID: 26210706
[TBL] [Abstract][Full Text] [Related]
7. Breast Cancer Risk and Follow-up Recommendations for Young Women Diagnosed with Atypical Hyperplasia and Lobular Carcinoma In Situ (LCIS).
McEvoy MP; Coopey SB; Mazzola E; Buckley J; Belli A; Polubriaginof F; Merrill AL; Tang R; Garber JE; Smith BL; Gadd MA; Specht MC; Guidi AJ; Roche CA; Hughes KS
Ann Surg Oncol; 2015 Oct; 22(10):3346-9. PubMed ID: 26242364
[TBL] [Abstract][Full Text] [Related]
8. Bisphosphonates, bone, and breast cancer recurrence.
Brufsky A; Mathew A
Lancet; 2015 Oct; 386(10001):1319-1320. PubMed ID: 26211825
[No Abstract] [Full Text] [Related]
9. Negative Genetic Testing Does Not Deter Contralateral Prophylactic Mastectomy in Younger Patients with Greater Family Histories of Breast Cancer.
Wang F; Amara D; Peled AW; Sbitany H; Foster RD; Ewing CA; Alvarado M; Esserman LJ
Ann Surg Oncol; 2015 Oct; 22(10):3338-45. PubMed ID: 26215194
[TBL] [Abstract][Full Text] [Related]
10. Impact of Adjuvant Chemotherapy on Breast Cancer Survival: A Real-World Population.
Rossi L; Stevens D; Pierga JY; Lerebours F; Reyal F; Robain M; Asselain B; Rouzier R
PLoS One; 2015; 10(7):e0132853. PubMed ID: 26214853
[TBL] [Abstract][Full Text] [Related]
11. Bilateral breast cancer, synchronous and metachronous; differences and outcome.
Jobsen JJ; van der Palen J; Ong F; Riemersma S; Struikmans H
Breast Cancer Res Treat; 2015 Sep; 153(2):277-83. PubMed ID: 26268697
[TBL] [Abstract][Full Text] [Related]
12. Complex fibroadenoma and breast cancer risk: a Mayo Clinic Benign Breast Disease Cohort Study.
Nassar A; Visscher DW; Degnim AC; Frank RD; Vierkant RA; Frost M; Radisky DC; Vachon CM; Kraft RA; Hartmann LC; Ghosh K
Breast Cancer Res Treat; 2015 Sep; 153(2):397-405. PubMed ID: 26264469
[TBL] [Abstract][Full Text] [Related]
13. Sentinel lymph node assessment in breast cancer patients receiving neo-adjuvant chemotherapy: to biopsy before or after?
Thorat MA
Int J Cancer; 2016 Jan; 138(2):267-70. PubMed ID: 26223486
[No Abstract] [Full Text] [Related]
14. Performance and Practice Guideline for the Use of Neoadjuvant Systemic Therapy in the Management of Breast Cancer.
Holmes D; Colfry A; Czerniecki B; Dickson-Witmer D; Francisco Espinel C; Feldman E; Gallagher K; Greenup R; Herrmann V; Kuerer H; Malik M; Manahan E; O'Neill J; Patel M; Sebastian M; Wheeler A; Kass R
Ann Surg Oncol; 2015 Oct; 22(10):3184-90. PubMed ID: 26224406
[TBL] [Abstract][Full Text] [Related]
15. Postmenopausal breast cancer: a best endocrine strategy?
Mayer EL; Burstein HJ
Lancet; 2015 Oct; 386(10001):1317-1319. PubMed ID: 26211823
[No Abstract] [Full Text] [Related]
16. Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial.
Bear HD; Tang G; Rastogi P; Geyer CE; Liu Q; Robidoux A; Baez-Diaz L; Brufsky AM; Mehta RS; Fehrenbacher L; Young JA; Senecal FM; Gaur R; Margolese RG; Adams PT; Gross HM; Costantino JP; Paik S; Swain SM; Mamounas EP; Wolmark N
Lancet Oncol; 2015 Sep; 16(9):1037-1048. PubMed ID: 26272770
[TBL] [Abstract][Full Text] [Related]
17. Breast Cancer Management Updates: Young and Older, Pregnant, or Male.
Dietz JR; Partridge AH; Gemignani ML; Javid SH; Kuerer HM
Ann Surg Oncol; 2015 Oct; 22(10):3219-24. PubMed ID: 26265366
[TBL] [Abstract][Full Text] [Related]
18. Breast-Conserving Surgery in Bilateral Breast Cancer.
O'Brien JA; Ho A; Wright GP; Stempel M; Patil S; Krause K; Morrow M; Gemignani ML
Ann Surg Oncol; 2015 Oct; 22(10):3389-96. PubMed ID: 26265365
[TBL] [Abstract][Full Text] [Related]
19. RE: Breast Cancer Risk After Salpingo-Oophorectomy in Healthy BRCA1/2 Mutation Carriers: Revisiting the Evidence for Risk Reduction.
Chai X; Domchek S; Kauff N; Rebbeck T; Chen J
J Natl Cancer Inst; 2015 Sep; 107(9):. PubMed ID: 26264690
[No Abstract] [Full Text] [Related]
20. The Manchester guidelines for contralateral risk-reducing mastectomy.
Basu NN; Ross GL; Evans DG; Barr L
World J Surg Oncol; 2015 Aug; 13():237. PubMed ID: 26245209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
